Studies have shown that active fund managers routinely underperform the S&P500 index*​

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)

ZNTL Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
85.90%

ZNTL Stock Analysis

ZNTL PE Ratio:

ZNTL PEG Ratio: Not Available

ZNTL Forward EPS Growth (12 month): 0.00%

ZNTL PS Ratio:

ZNTL PSG Ratio: Not Available

ZNTL Forward Revenue Growth (12 month): 0.00%

ZNTL Articles

No data was found